Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Change in Acquisitions & Divestments (2017 - 2026)

Cogent Biosciences' Change in Acquisitions & Divestments history spans 7 years, with the latest figure at $97.8 million for Q1 2026.

  • Quarterly Change in Acquisitions & Divestments rose 39.91% to $97.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $317.1 million through Mar 2026, up 9.25% year-over-year, with the annual reading at $289.2 million for FY2025, 1.78% down from the prior year.
  • Change in Acquisitions & Divestments came in at $97.8 million for Q1 2026, up from $73.3 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $120.0 million in Q1 2023 to a low of $22.1 million in Q3 2023.
  • The 4-year median for Change in Acquisitions & Divestments is $73.3 million (2025), against an average of $71.9 million.
  • The largest YoY upside for Change in Acquisitions & Divestments was 262.41% in 2024 against a maximum downside of 38.23% in 2024.
  • Cogent Biosciences' Change in Acquisitions & Divestments stood at $61.7 million in 2023, then increased by 20.66% to $74.5 million in 2024, then fell by 1.62% to $73.3 million in 2025, then surged by 33.53% to $97.8 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Change in Acquisitions & Divestments are $97.8 million (Q1 2026), $73.3 million (Q4 2025), and $69.1 million (Q3 2025).